|Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study|
E Esposito, P Mariani, L Ravani, C Contado, M Volta, S Bido, M Drechsler, ...
European journal of pharmaceutics and biopharmaceutics 80 (2), 306-314, 2012
|In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels|
F Mela, M Marti, S Bido, MA Cenci, M Morari
Neurobiology of disease 45 (1), 573-582, 2012
|Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels|
S Bido, M Marti, M Morari
Journal of neurochemistry 118 (6), 1043-1055, 2011
|Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease|
NM Urs, S Bido, SM Peterson, TL Daigle, CE Bass, RR Gainetdinov, ...
Proceedings of the National Academy of Sciences 112 (19), E2517-E2526, 2015
|Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression|
M Bourdenx, S Dovero, M Engeln, S Bido, MF Bastide, N Dutheil, ...
Acta neuropathologica communications 3 (1), 46, 2015
|Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson’s disease models|
A Iannielli, S Bido, L Folladori, A Segnali, C Cancellieri, A Maresca, ...
Cell reports 22 (8), 2066-2079, 2018
|AAV-PHP. B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy|
G Morabito, SG Giannelli, G Ordazzo, S Bido, V Castoldi, M Indrigo, ...
Molecular Therapy 25 (12), 2727-2742, 2017
|Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease|
S Bido, FN Soria, RZ Fan, E Bezard, K Tieu
Scientific reports 7 (1), 1-13, 2017
|Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice|
M Volta, OS Mabrouk, S Bido, M Marti, M Morari
Journal of neurochemistry 115 (6), 1543-1555, 2010
|Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease|
L Arcuri, R Viaro, S Bido, F Longo, M Calcagno, PO Fernagut, NT Zaveri, ...
Neurobiology of disease 89, 55-64, 2016
|Differential involvement of Ras‐GRF1 and Ras‐GRF2 in L‐DOPA‐induced dyskinesia|
S Bido, N Solari, M Indrigo, A D'Antoni, R Brambilla, M Morari, S Fasano
Annals of clinical and translational neurology 2 (6), 662-678, 2015
|D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly|
P Barroso-Chinea, ML Thiolat, S Bido, A Martinez, E Doudnikoff, ...
Neurobiology of disease 78, 77-87, 2015
|Striatal NELF-mediated RNA polymerase II stalling controls l-dopa induced dyskinesia|
MF Bastide, S Bido, N Duteil, E Bézard
Neurobiology of disease 85, 93-98, 2016
|dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice|
G Colasante, G Lignani, S Brusco, C Di Berardino, J Carpenter, ...
Molecular Therapy 28 (1), 235-253, 2020
|Reconstitution of the Human Nigro-striatal Pathway on-a-Chip Reveals OPA1-Dependent Mitochondrial Defects and Loss of Dopaminergic Synapses|
A Iannielli, GS Ugolini, C Cordiglieri, S Bido, A Rubio, G Colasante, ...
Cell Reports 29 (13), 4646-4656. e4, 2019
|Novel gene therapy approaches for whole brain delivery of the lysosomal GCase enzyme for wide protection from alpha-synuclein toxic aggregates|
G Ordazzo, S Bido, M Valtorta, G Rossi, G Morabito, S Giannelli, ...
HUMAN GENE THERAPY 29 (12), A143-A143, 2018
|AAV. PHP. eB-mediated OPA1 gene expression in a mouse model of Parkinson's disease as a valuable strategy for neuroprotection|
L Arcuri, S Giannelli, S Bido, M Valtorta, G Ordazzo, G Rossi, V Broccoli
HUMAN GENE THERAPY 29 (12), A91-A91, 2018
|A novel AAV design improving efficiency and safety in a gene therapy approach for Rett syndrome in a mouse model|
SG Giannelli, M Luoni, G Morabito, S Bido, M Indrigo, A Niro, R Ricci, ...
HUMAN GENE THERAPY 29 (12), A79-A80, 2018
|Changing the Face of Modern Medicine: Stem Cell and Gene Therapy Organized Jointly by the European Society of Gene & Cell Therapy (ESGCT), International Society for Stem Cell …|
KM Champion, P Albertini, I Visigalli, F Cecere, N Carriglio, ...
Human Gene Therapy 29 (12), A1-A169, 2018
|Novel Gene Therapy Approaches for Whole Brain Delivery of the Lysosomal Gcase Enzyme for Wide Protection from Alpha-Synuclein Toxic Aggregates|
V Broccoli, G Ordazzo, S Bido, M Valtorta, G Morabito, J Koerbelin, ...
MOLECULAR THERAPY 26 (5), 131-131, 2018